Differential regulation of human basophil and lung mast cell function by adenosine.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 1704436)

Published in J Pharmacol Exp Ther on February 01, 1991

Authors

P T Peachell1, L M Lichtenstein, R P Schleimer

Author Affiliations

1: Johns Hopkins Asthma and Allergy Center, Clinical Immunology Division, Baltimore, Maryland 21224.

Articles citing this

Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest (1995) 2.01

Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med (2007) 1.26

Adenosine receptors and asthma. Br J Pharmacol (2008) 1.14

Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur J Immunol (2007) 1.04

Purinergic signalling and immune cells. Purinergic Signal (2014) 0.94

Adenosine A2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol (1996) 0.86

Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation. Front Immunol (2012) 0.83

IL-4 amplifies the pro-inflammatory effect of adenosine in human mast cells by changing expression levels of adenosine receptors. PLoS One (2011) 0.81

Reciprocal modulation of anti-IgE induced histamine release from human mast cells by A₁ and A(2B) adenosine receptors. Br J Pharmacol (2011) 0.79

The role of activated adenosine receptors in degranulation of human LAD2 mast cells. Purinergic Signal (2014) 0.77

Role of endogenous adenosine in the acute and late response to allergen challenge in actively sensitized Brown Norway rats. Br J Pharmacol (2003) 0.77

Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation. J Pharmacol Exp Ther (2012) 0.76

Articles by these authors

Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38

Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31

The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51

Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. J Immunol (1986) 3.41

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91

Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76

Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70

A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65

Anaphylaxis. N Engl J Med (1991) 2.53

Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47

Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38

Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37

The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35

A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33

Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19

IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18

Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17

Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16

Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13

A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05

Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05

The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02

Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98

Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95

Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94

The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93

Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor. Infect Immun (1998) 1.87

Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84

Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84

Epidemiology of insect venom sensitivity. JAMA (1989) 1.83

Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells. J Immunol (1999) 1.83

Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80

Human lung mast cells: purification and characterization. J Immunol (1982) 1.78

The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78

Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77

The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73

The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol (1992) 1.72

Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72

IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71

Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70

Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol (1988) 1.68

IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol (1995) 1.68

The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67

Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65

Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63

Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63

IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58

Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58

Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55

Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54

Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol (2000) 1.52

Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52

In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50

Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48

Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47

Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46

Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol (2000) 1.46

Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol (1976) 1.45

The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol (1975) 1.45

Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45

Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol (1991) 1.45

Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol (1994) 1.44

Kinins are generated during experimental rhinovirus colds. J Infect Dis (1988) 1.44

Properties of a subpopulation of T cells bearing histamine receptors. J Clin Invest (1975) 1.43

Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis (1988) 1.43

Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol (2001) 1.42

Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med (1969) 1.42

Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy (2010) 1.41

Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. J Immunol (1966) 1.41

Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy (1993) 1.41

Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest (1983) 1.41

Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40

Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med (1981) 1.40

Induction of histamine secretion by polycations. Biochim Biophys Acta (1980) 1.39

Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J Immunol (1994) 1.38

Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. J Immunol (1992) 1.38

Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis (1991) 1.38

Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med (1984) 1.38

Heterogeneity of human mast cells. J Immunol (1983) 1.37

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37

Insect allergy: the state of the art. J Allergy Clin Immunol (1979) 1.35

Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol (1995) 1.33

Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33

Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32

Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol (1987) 1.32

Recombinant IL-3 induces histamine release from human basophils. J Immunol (1989) 1.31

Studies on the mechanism of lymphocyte-mediated cytolysis. 3. The role of microfilaments and microtubules. J Immunol (1973) 1.31

Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood (1995) 1.30

Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. J Allergy Clin Immunol (1974) 1.30

A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol (1968) 1.28